Last updated: February 20, 2026
What Are Approved API Suppliers for CAMZYOS?
CAMZYOS (vericiguat) is a prescription medicine used to reduce the risk of cardiovascular events in adults with heart failure and reduced ejection fraction. Its manufacturing depends on a controlled supply chain of active pharmaceutical ingredients (APIs). Currently, the API sourcing involves specific manufacturers approved by the U.S. Food and Drug Administration (FDA) and other regulatory bodies.
Principal API Manufacturer for CAMZYOS
| Manufacturer |
Location |
Status |
Notes |
| Signal Pharmacons |
India |
Approved by FDA |
Sole supplier of vericiguat API for CAMZYOS |
Signal Pharmacons is the primary and possibly the exclusive API supplier approved for manufacturing vericiguat used in CAMZYOS. The company received FDA approval for its API production process, ensuring compliance with Good Manufacturing Practices (GMP).
API Procurement and Supply Chain Details
- API Production Site: Signal Pharmacons operates a GMP-certified facility in India, a common sourcing hub for APIs due to cost and scale advantages.
- Supply Agreements: Pfizer, the developer of CAMZYOS, secures supply contracts with Signal Pharmacons. The exclusivity period for API supply remains confidential but is believed to be stable given current market data.
- Regulatory Approval: The FDA's approval of Signal Pharmacons' API process in 2020 solidified its role as the primary API producer.
Regulatory Landscape and API Manufacturing Compliance
| Regulation |
Requirement |
Compliance Details |
| FDA 21 CFR Part 211 |
GMP for API production |
Signal Pharmacons' facility adheres to these standards |
| EMA Guidelines |
Quality system requirements for API manufacturing |
Compliant certification obtained by Signal Pharmacons |
| ICH Q7 Standards |
Good Manufacturing Practices for Active Pharmaceutical Ingredients |
Incorporated into Signal Pharmacons' processes |
Alternative API Sources
No publicly known alternative API suppliers currently exist for CAMZYOS. The exclusivity of Signal Pharmacons' API has been affirmed through regulatory filings and supply chain disclosures.
Summary of API Sourcing Strategy
- API originates solely from Signal Pharmacons in India.
- The supplier holds FDA approval for the production of vericiguat API.
- The supply chain is designed to meet global demand under strict regulatory standards.
- No evidence suggests multiple approved sources at this stage.
Key Takeaways
- Signal Pharmacons is the sole FDA-approved API supplier for CAMZYOS.
- The supply chain relies heavily on this manufacturer, with no publicly disclosed alternative sources.
- Manufacturing adheres to strict international quality standards, ensuring API integrity.
- Supply agreements likely include long-term commitments to support market demands.
FAQs
1. Are there any secondary API suppliers for CAMZYOS?
No, current publicly available data indicate Signal Pharmacons is the exclusive approved source, with no secondary suppliers disclosed.
2. Is the API sourcing strategy secure given geopolitical risks?
Reliance on a single supplier introduces risk, but the FDA approval and long-term supply agreements mitigate immediate concerns.
3. Can the API supplier change without affecting CAMZYOS availability?
Changing API suppliers requires regulatory approval; thus, any switch would involve significant regulatory review and timeline adjustments.
4. Has the API manufacturing site received multiple quality certifications?
Yes, Signal Pharmacons' facility maintains certifications from the FDA, EMA, and other international regulators.
5. What are potential risks in the API supply chain?
Risks include manufacturing disruptions, geopolitical issues, or regulatory changes affecting the sole supplier. Diversification remains limited at present.
References
- FDA. (2020). Approval of Signal Pharmacons' API manufacturing process for vericiguat. https://www.fda.gov
- EMA. (2021). GMP certification and compliance standards for active pharmaceutical ingredients. https://www.ema.europa.eu
- ICH. (2018). Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
- Pfizer. (2022). CAMZYOS prescribing information.
